Institute of Diagnostic and Interventional Radiology Shanghai Jiao Tong University Affiliated Sixth People's Hospital Shanghai China.
Department of Cardiology Shanghai Jiao Tong University Affiliated Sixth People's Hospital Shanghai China.
J Am Heart Assoc. 2020 May 18;9(10):e015772. doi: 10.1161/JAHA.120.015772. Epub 2020 May 8.
Background Whether statin treatment can improve hemodynamic status of coronary atherosclerotic plaque remains unknown. It is of clinical interest to explore the hemodynamic change of coronary lesions after statin treatment. Methods and Results Consecutive patients with intermediate pre-test probability of coronary artery disease were prospectively enrolled and underwent baseline coronary computed tomography angiography (CCTA) as well as follow-up CCTA. The primary end point was to determine the lesion-specific change of △computed tomography-derived fractional flow reserve (△CT-FFR, defined as the change of CT-FFR value across each lesion) after rosuvastatin treatment. The secondary end point was to compare the change of other plaque characteristics according to serial CCTA findings. 152 patients (mean age: 67.1±9.7 years, 100 men, mean follow-up duration of 13.9±2.5 months) were finally included. In non-calcified plaque subgroup, △CT-FFR was significantly lower at follow-up compared with baseline (0.051±0.010 versus 0.035±0.012, =0.013). All other parameters were not found to be significantly different between baseline and follow-up CCTA measurements. In calcified plaque and mixed plaque subgroups, all parameters showed no significant differences between baseline and follow-up CCTA groups (>0.05 for all). According to multivariate regression analysis, non-calcified plaque was >2 times more likely than calcified plaque to observe the decrease of △CT-FFR (adjusted hazard ratio: 2.05 [1.03-4.09], =0.042). Conclusions In patients with mild to intermediate coronary stenosis, rosuvastatin treatment resulted in a reduction in lesion-specific △CT-FFR at mid-term follow-up. This hemodynamic improvement was mainly observed for non-calcified lesions.
他汀类药物治疗能否改善冠状动脉粥样硬化斑块的血流动力学状态尚不清楚。探索他汀类药物治疗后冠状动脉病变的血流动力学变化具有临床意义。
连续纳入具有中等程度冠状动脉疾病预测前概率的患者,前瞻性地进行基线冠状动脉计算机断层血管造影(CCTA)和随访 CCTA。主要终点是确定瑞舒伐他汀治疗后病变特异性的△计算机断层血流储备分数(△CT-FFR,定义为每个病变的 CT-FFR 值变化)。次要终点是根据连续 CCTA 结果比较其他斑块特征的变化。最终纳入 152 例患者(平均年龄:67.1±9.7 岁,100 例男性,平均随访时间为 13.9±2.5 个月)。在非钙化斑块亚组中,与基线相比,随访时的△CT-FFR 显著降低(0.051±0.010 比 0.035±0.012,=0.013)。其他所有参数在基线和随访 CCTA 测量之间均未发现显著差异。在钙化斑块和混合斑块亚组中,所有参数在基线和随访 CCTA 组之间均无显著差异(所有>0.05)。根据多变量回归分析,与钙化斑块相比,非钙化斑块观察到△CT-FFR 降低的可能性增加了 2 倍以上(调整后的危险比:2.05[1.03-4.09],=0.042)。
在轻至中度冠状动脉狭窄的患者中,瑞舒伐他汀治疗在中期随访时导致病变特异性△CT-FFR 降低。这种血流动力学改善主要发生在非钙化病变。